125 related articles for article (PubMed ID: 25734660)
1. Promising management of pazopanib-induced liver toxicity.
Vlenterie M; van Erp NP; van der Graaf WT
Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
[No Abstract] [Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
3. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract][Full Text] [Related]
4. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
[TBL] [Abstract][Full Text] [Related]
6. Response of refractory Ewing sarcoma to pazopanib.
Alcindor T
Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
[No Abstract] [Full Text] [Related]
7. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
[TBL] [Abstract][Full Text] [Related]
8. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
Miura H; Shirai H
Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
[No Abstract] [Full Text] [Related]
9. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
10. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
11. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
[TBL] [Abstract][Full Text] [Related]
12. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
13. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
[No Abstract] [Full Text] [Related]
14. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
[TBL] [Abstract][Full Text] [Related]
15. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
[No Abstract] [Full Text] [Related]
16. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
[TBL] [Abstract][Full Text] [Related]
17. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
Cohen L; Neuhaus S; Chryssidis S; Kotasek D
ANZ J Surg; 2017 Jul; 87(7-8):E48-E49. PubMed ID: 25556827
[No Abstract] [Full Text] [Related]
18. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
[No Abstract] [Full Text] [Related]
[Next] [New Search]